[{"address1": "611 Gateway Boulevard", "address2": "Suite 273", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "415-910-5717", "website": "https://www.quincetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Dr. Dirk  Thye M.D.", "age": 53, "title": "CEO, Chief Medical Officer & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 856500, "exercisedValue": 0, "unexercisedValue": 83318}, {"maxAge": 1, "name": "Dr. Charles S. Ryan J.D., Ph.D.", "age": 59, "title": "President", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 524468, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan  Hannah M.B.A.", "age": 37, "title": "Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer", "yearBorn": 1986, "fiscalYear": 2023, "totalPay": 607500, "exercisedValue": 0, "unexercisedValue": 35497}, {"maxAge": 1, "name": "Mr. Giovanni  Mambrini M.Sc.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Guenter R. Janhofer M.D., Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stacy  Roughan", "title": "Vice President of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary Ellen Sillivos", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stewart A. Low Ph.D.", "title": "Head of Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas  Sabia M.B.A.", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pamela M. Williamson FRAPS, M.B.A., RAC", "title": "Head of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.19, "open": 1.03, "dayLow": 0.9691, "dayHigh": 1.3, "regularMarketPreviousClose": 1.19, "regularMarketOpen": 1.03, "regularMarketDayLow": 0.9691, "regularMarketDayHigh": 1.3, "beta": 0.855, "forwardPE": -3.483871, "volume": 1098641, "regularMarketVolume": 1098641, "averageVolume": 289140, "averageVolume10days": 890620, "averageDailyVolume10Day": 890620, "marketCap": 46738728, "fiftyTwoWeekLow": 0.512, "fiftyTwoWeekHigh": 1.43, "fiftyDayAverage": 0.7504, "twoHundredDayAverage": 0.930415, "currency": "USD", "enterpriseValue": 1674734, "floatShares": 34603109, "sharesOutstanding": 43276600, "sharesShort": 1911224, "sharesShortPriorMonth": 1963463, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0442, "heldPercentInsiders": 0.13744001, "heldPercentInstitutions": 0.25244, "shortRatio": 30.08, "shortPercentOfFloat": 0.0478, "impliedSharesOutstanding": 43276600, "bookValue": 1.085, "priceToBook": 0.9953917, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -53123000, "trailingEps": -1.26, "forwardEps": -0.31, "pegRatio": -0.06, "enterpriseToEbitda": -0.057, "52WeekChange": 0.10769236, "SandP52WeekChange": 0.39389753, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "QNCX", "underlyingSymbol": "QNCX", "shortName": "Quince Therapeutics, Inc.", "longName": "Quince Therapeutics, Inc.", "firstTradeDateEpochUtc": 1557408600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "da44f040-5883-3598-bd5c-37ccfbaf9c2e", "messageBoardId": "finmb_266230063", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.08, "targetHighPrice": 12.0, "targetLowPrice": 12.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 59445000, "totalCashPerShare": 1.374, "ebitda": -29129000, "totalDebt": 14381000, "quickRatio": 5.853, "currentRatio": 6.146, "debtToEquity": 30.619, "returnOnAssets": -0.16496, "returnOnEquity": -0.79376, "freeCashflow": -7836125, "operatingCashflow": -27988000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]